Key result
In postinfarction patients with a high-risk triangular index (<20) and low-risk alpha (<median), prophylactic amiodarone significantly reduced mortality compared to placebo (8.7% vs 24.2%, p=0.017).
Why the study?
Does prophylactic amiodarone improve survival in post-myocardial infarction patients stratified by HRV scaling exponent (alpha) and triangular index?
Population
Post-myocardial infarction patients from the European Myocardial Infarction Amiodarone Trial (EMIAT)
Comparison
Amiodarone vs Placebo
Design
Cohort
Authors
Loading...
May support amiodarone in this HRV-defined post-MI subgroup; leaves open confirmation by randomized trials.
Cohort
Yes
Does prophylactic amiodarone improve survival in post-myocardial infarction patients stratified by HRV scaling exponent (alpha) and triangular index?
Absolute Event Rate: 8.7% vs 24.2%
p-value: p=0.017
Combining HRV triangular index and the scaling exponent alpha identifies a specific subgroup of post-myocardial infarction patients who derive substantial survival benefit from prophylactic amiodarone.
Sassi et al. (2005) conducted a cohort in Acute myocardial infarction. Amiodarone vs. Placebo was evaluated on Mortality (p=0.017). In postinfarction patients with a high-risk triangular index (<20) and low-risk alpha (<median), prophylactic amiodarone significantly reduced mortality compared to placebo (8.7% vs 24.2%, p=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: